PS02.122: PREOPERATIVE CHEMOTHERAPY WITH BIWEEKLY DOCETAXEL, CISPLATIN, AND 5-FLUOROURACIL FOR ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Sign Up to like & getrecommendations! Published in 2018 at "Diseases of the Esophagus"
DOI: 10.1093/dote/doy089.ps02.122
Abstract: Docetaxel, cisplatin, and 5-fluorouracil (DCF) therapy can have severe adverse events, including neutropenia and febrile neutropenia. Feasibility of DCF is a concern especially for elderly patients, patients with moderate organ disorder, and those with dysphagia… read more here.
Keywords: group; therapy; docetaxel cisplatin; bdcf group ... See more keywords